HKSE · 1875.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 03:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
BioDlink International Company Limited’s quoted price sits in the lower half of its reported 52-week range, 43.95% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
BioDlink International Company Limited’s next earnings report is currently expected on Mar 25, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow BioDlink International Company Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
BioDlink International Co., Ltd. operates as a clinical-stage biopharmaceutical firm, dedicating its resources to the development and future commercialization of novel oncology drugs and therapeutic solutions. Its pipeline features several key product candidates, including TAB008, TOZ309, TAA013, TAE020, TAB 014, and TAC020. The company was founded on December 4, 2009, and its primary base of operations is situated in Suzhou, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:15 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2022 |
|---|
| Aug 13, 2022 |
| -HK$0.03 |
| HK$213.08M |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$436.80-HK$1.00 (-0.23%)
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 22.35% below the high.
HK$28.02-HK$0.20 (-0.71%)
Ascentage Pharma Group International’s quoted price sits in the lower half of its reported 52-week range, 59.6% below the high.
HK$5.05+HK$0.31 (+6.55%)
CStone Pharmaceuticals’s quoted price sits in the lower half of its reported 52-week range, 51.54% below the high.
HK$3.21+HK$0.14 (+4.57%)
Lepu Biopharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 53.42% below the high.
HK$8.82+HK$0.17 (+1.91%)
TransThera Sciences (Nanjing). Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.41% below the high.
HK$1.58HK$0.00 (0.0%)
Edding Genor Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 59.62% below the high.
HK$3.15-HK$0.01 (-0.16%)
TYK Medicines, Inc’s quoted price sits in the lower half of its reported 52-week range, 80.01% below the high.
HK$3.50-HK$0.05 (-1.41%)
Beijing Biostar Pharms Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 33.33% below the high.
